FENNEC PHARMACEUTICALS INC (FRX.CA) Stock Analyst Ratings
Canada - TSX:FRX - CA31447P1009 - Common Stock
12.33 CAD
0 (0%)
ChartMill assigns a Buy % Consensus number of 85% to FRX.CA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 19.63. This target is 59.24% above the current price.
FRX.CA was analyzed by 11 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about FRX.CA.
In the previous month the buy percentage consensus was at a similar level.
FRX.CA was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-11-23 | Cantor Fitzgerald Securities | Upgrade | Overweight |
| 2021-06-03 | HC Wainwright & Co. | Maintains | Buy |
| 2021-04-21 | Craig-Hallum | Initiate | Buy |
| 2021-04-19 | Maxim Group | Initiate | Buy |
FENNEC PHARMACEUTICALS INC / FRX.CA FAQ
What is the average price target for FENNEC PHARMACEUTICALS INC (FRX.CA) stock?
11 analysts have analysed FRX.CA and the average price target is 19.63 CAD. This implies a price increase of 59.24% is expected in the next year compared to the current price of 12.33.
Can you provide the consensus rating for FENNEC PHARMACEUTICALS INC stock?
The consensus rating for FENNEC PHARMACEUTICALS INC (FRX.CA) is 85.4545 / 100 . This indicates that analysts generally have a positive outlook on the stock.